The story of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial launch generated massive profits, the expiration of its patent opened the avenue to generic versions, https://bookmarkswing.com/story23400360/the-copyright-and-big-pharma-a-precarious-opportunity